255 results about "Bile fluid" patented technology

The invention discloses a filtering device for reinfusion after external drainage of bile in the hepatobiliary surgery department, and belongs to the technical field of medical instruments. The filtering device comprises a drainage mechanism, a stepped filtering mechanism and a reinfusion mechanism. The stepped filtering mechanism is used for filtering bile; the stepped filtering mechanism is detachably connected with the drainage mechanism and the feedback mechanism. The stepped filtering mechanism comprises a filtering carrier, a filtering cavity and a pumping mechanism used for pumping bile to the filtering cavity are arranged in the filtering carrier, a primary screen, a hollow fiber membrane and a hydrophilic gel filtering membrane are sequentially arranged in the filtering cavity from top to bottom, and a cleaning mechanism used for cleaning the primary screen is arranged on one side of the primary screen. An ultrasonic vibration module for cleaning attachments on the hollow fiber membrane is arranged on one side of the hollow fiber membrane. By means of the intelligent design and the multi-stage filtering mechanism, the bile feedback efficiency and safety are remarkably improved, and the infection risk is reduced.

The invention belongs to the technical field of in-vitro cultivation of calculus bovis, and particularly relates to a method for in-vitro cultivation of calculus bovis. According to the invention, firstly, the escherichia coli is subjected to bile domestication and ray induced mutation, a high-activity oxgall-resistant bezoar production engineering bacterium E.coli-NH01 is obtained through screening, a method for in-vitro cultivation of bezoar by using the engineering bacterium E.coli-NH01 is provided, the prepared bezoar meets the pharmacopoeia standard, the production efficiency of in-vitro cultivation of bezoar is improved, and the production cost is reduced. And the production cost is reduced, the overall forming period is shortened, and the key that precious traditional Chinese medicinal materials are popular can be achieved.

The invention relates to the field of bile monitoring and analysis, in particular to a dynamic bile monitoring and analysis method and device based on real-time image recognition. The method comprises the following steps: continuously collecting a bile monitoring image sequence of a drainage bag of a patient, and carrying out global image resolution optimization and multi-frame color drift analysis to obtain a multi-time-point bile color evolution sequence; performing comprehensive bile physical state vector modeling according to the bile monitoring image sequence, performing personalized bile state characteristic evolution, and constructing a bile color-property comprehensive characteristic spectrum; and performing deep color component visual detection based on the multi-time-point bile color evolution sequence, performing pathological concentration change mining, and constructing a concentration anomaly evolution model. According to the method, the real-time bile state characteristics of the patient are accurately analyzed based on precision visual identification, the risk level and deterioration prediction are combined, the dynamic adjustment of the precise early warning time point is realized, and the response speed and the early warning accuracy are improved.

1. The name of the product of this design: bile duct drainage tube. 2. Purpose of the product of this design: A disposable soft catheter used for drainage of bile after common bile duct incision and exploration. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention discloses an application of probiotics in preparation of a medicine for preventing and / or treating cholestatic liver diseases. The probiotics are selected from one or more of plant lactobacillus Lp-G18, bifidobacterium longum subsp. Longum BL-G301, lactobacillus reuteri LR-G100 and lactobacillus johnsonii LJ-G55. Preferably, the cholestatic liver disease is primary biliary cholangitis.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention relates to the technical field of medical instruments, in particular to an intelligent bile flow monitoring T tube which comprises a microprocessor and a T tube body, a pressure sensor is arranged in the T tube body, the T tube body is formed by communicating a transverse tube and a longitudinal tube, the two ends of the transverse tube are close to the bile duct and the intestinal tract of the liver respectively, and drainage is conducted to the outside from the end of the longitudinal tube. A first flow sensor is arranged on the transverse tube close to the liver bile duct to measure the total flow of bile, a second flow sensor is arranged close to the intestinal tract to measure the amount of bile flowing into the intestinal tract, and a third flow sensor is arranged in the longitudinal tube to measure the flow of bile discharged out of the body. The microprocessor collects and analyzes sensor data through the information collecting and processing module so as to calculate bile flow and pressure, and judges the bile flow direction condition when the third flow sensor data is abnormal. The bile monitoring precision can be improved, in-vitro drainage amount abnormity can be quickly diagnosed, the postoperative management efficiency is enhanced, the complication risk is reduced, the postoperative safety of a patient is improved, and the function and reliability of a bile drainage system are improved by means of an innovative technology.

The invention relates to the technical field of intelligent medical care, and discloses a drainage port nursing recommendation method and system for a patient with bile leakage. The system comprises a data acquisition module used for acquiring bile drainage data and state data of skin around a drainage port in real time; the cloud decision module is internally provided with a nursing scheme recommendation model associated with a bile leakage nursing knowledge graph, and is used for carrying out fusion analysis on the multi-modal data and generating a personalized nursing plan; the local execution terminal is used for receiving and displaying the nursing plan and guiding nursing personnel to execute and record actual nursing operation data; and the closed-loop feedback module is used for returning the actual execution data and the post-nursing state data so as to optimize the nursing scheme recommendation model and the bile leakage nursing knowledge graph. The technical problems that in traditional nursing, evaluation is subjective, decision-making depends on experience, execution is not standard, and knowledge is difficult to accumulate are solved, and standardization, individuation and continuous self-optimization of bile leakage drainage opening nursing are achieved.

The invention discloses a biliary drainage reinfusion device which comprises a nasobiliary duct, a drainage bag, a sealing cylinder, a heating mechanism, a filtering mechanism and a reinfusion tube, the drainage bag is arranged at the output end of the nasobiliary duct, the sealing cylinder is connected to the output end of the drainage bag, and the heating mechanism and the filtering mechanism are arranged in the sealing cylinder. And the feedback pipe is connected to the output end of the sealing cylinder and is used for feeding back the heated and filtered bile into the body of the patient. By arranging the heating mechanism and the filtering mechanism, bile which is drained and returned is heated and filtered, impurities such as tissue fragments in the bile are removed and intercepted, the bile is prevented from entering the body of a patient, meanwhile, pipeline blockage caused by thick bile is avoided, discomfort caused by the fact that low-temperature bile enters the human body is reduced by heating the bile, and the treatment effect is good. The activity of enzymes in the bile is maintained. And by arranging the feedback tube, the integral closed drainage feedback device is realized, and the pollution is reduced.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The utility model provides a self-discharging type double-helix biliary stent, and belongs to the technical field of medical drainage catheters. Comprising a stent body, and the stent body comprises a connecting pipe, a first spiral pipe and a second spiral pipe; the connecting pipe is used for fixedly connecting the first spiral pipe and the second spiral pipe; the first spiral tube is mounted on one side of the connecting tube and used for draining bile; the second spiral pipe is installed on the side, away from the first spiral pipe, of the connecting pipe. Compared with an existing double-pigtail stent or a self-discharging type biliary tract spiral stent, the spiral structure of the two sets of spiral tubes can better adapt to the physiological form of the biliary tract, stable fixation is formed, the risk that an original stent with one end being of a vertical structure possibly pierces the intestinal wall is avoided, and the intestinal tract can be more stably fixed. Due to the arrangement of the self-discharging double-helix biliary stent, convenience is provided for taking out the stent subsequently.

The utility model relates to the technical field of medical instruments, in particular to a multifunctional biliary tract drainage tube with double-cavity sacculus auxiliary expansion through a PTCD (percutaneous transluminal compact disc) way, which comprises a drainage tube, a sacculus expansion tube group, a water injection tube and a sacculus, the fixing shell set comprises a drainage tube fixing shell and a water injection tube fixing shell arranged on the periphery of the drainage tube fixing shell, the drainage tube fixing shell is connected with the drainage tube, and the water injection tube fixing shell is connected with the water injection tube; the internal and external intercommunication window is communicated with a first area on the drainage tube and a second area, corresponding to each other, on the water injection tube, so that bile outside the water injection tube flows into the drainage tube through the internal and external intercommunication window. The multifunctional biliary tract drainage tube for assisting expansion through the PTCD way double-cavity balloon integrates biliary tract expansion and bile drainage, operation is reduced, and operation cost can be greatly reduced.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention relates to the technical field of biology, and particularly discloses a gene Panel sequencing method for intrahepatic cholestasis in a gestation period, which comprises the following steps: collecting saliva, performing DNA extraction and purification on a sample, breaking the purified sample, treating the broken sample to obtain a supernatant A, performing linker connection and purification on the supernatant A to obtain a supernatant B, and sequencing the supernatant B to obtain the gene Panel of intrahepatic cholestasis in a gestation period. The invention relates to a Panel detection technology for detecting 186 cholestasis genes covering bile acid metabolism, which comprises the following steps: preparing a supernatant B, carrying out pre-PCR and purification treatment on the supernatant B to obtain a pre-PCR product, carrying out liquid phase hybridization and capture, configuring a PCR reaction system, carrying out Post-PCR reaction and purification to obtain a supernatant C, quantifying the supernatant C, screening ICP susceptible genes through mixed sample sequencing, collecting DNA (Deoxyribonucleic Acid) through a saliva sampling mode, and detecting the 186 cholestasis genes covering bile acid metabolism. Other hereditary intrahepatic cholestasis diseases can be excluded, and ICP genetics susceptibility genes are defined.

The invention discloses a postoperative recurrence monitoring system and method for bile liquid biopsy, and relates to the technical field of medical detection, and the method comprises the following steps: obtaining medication data, bile liquid data and gene data of a target object; preprocessing the medication data and the bile liquid data to generate a sampling interference index sequence, and further performing weighted fusion on the gene data by the sampling interference index sequence to obtain a mutation load index of each gene detection time point; and within the time sequence range of the gene data, performing sliding window analysis on the sampling interference index sequence to generate an abnormal chain marker sequence. According to the method, the time sequence mismatch degree is accurately quantified by constructing a time difference matrix, and a weight distribution mechanism is dynamically adjusted in combination with medication volatility, so that the generation process of the sampling interference index can adaptively reflect the influence of medication mode change on the sampling quality; the problem of interference evaluation deviation caused by mismatching of medication data and bile sampling time is effectively solved.

The application relates to the technical field of biological pharmacy, and discloses a method for preparing high-bionic bovine bezoar by using a 3D printing technology and application. The preparation raw material of the high-bionic bovine bezoar comprises the following components: fermented bovine bile, saturated calcium hydroxide, hydroxypropyl methyl cellulose, bilirubin, cholic acid, deoxycholic acid and taurine; wherein the fermented bovine bile is obtained by fermenting bovine bile by using escherichia coli. The high-bionic bovine bezoar prepared by using the preparation raw material to perform 3D printing can be comparable to natural bovine bezoar in terms of components, effects and appearance, the main pharmaceutical components can be adjusted according to actual requirements, the production cost of the bovine bezoar can be greatly reduced, and the demand of people for the bovine bezoar can be met.

This article provides methods for treating progressive familial intrahepatic cholestasis of blood (PFIC), including, for example, PFIC2 (bial salt export pump (BSEP) deficiency), using ileal bile acid transport (IBAT) inhibitors (such as ozexibart or a pharmaceutically acceptable salt thereof). These methods may include identifying or selecting subjects with a higher percentage of unconjugated serum bile acids relative to a reference level and administering an IBAT inhibitor to the identified or selected subject.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The subject matter disclosed describes a method of treating pruritus in a subject with cholestatic liver disease in need thereof, comprising administering a therapeutically effective amount of nalmefene to the subject, wherein the subject achieves an improvement in pruritus within 24 hours following administration of nalmefene.

The invention provides a bile sample preservation method. The method comprises the following steps: collecting a bile sample; and mixing the bile sample with a nucleic acid protective agent, and preserving at the temperature of 25-80 DEG C. The invention aims to design a plurality of storage conditions for storing bile from the presence / absence of a bile nucleic acid protective agent, different storage temperature gradients, different storage time periods and the like, and further preliminarily explores the stability of the bile cfDNA, so as to determine the condition for stably storing the bile cfDNA, and provide a foundation for subsequent application of the bile cfDNA to liquid biopsy. And corresponding technical support is provided for the aspects of early clinical diagnosis, prognosis monitoring and the like of patients with malignant biliary tract tumors.

The invention discloses CCL2, a receptor specific binding polypeptide thereof and application of the receptor specific binding polypeptide in prevention and treatment of cholestatic liver diseases, and relates to the technical field of biological medicines. The CCL2 and the receptor specific binding polypeptide thereof, which are screened by a molecular simulation technology, can be specifically bound with a key molecule CCL2 for inducing diseases and a plurality of receptors thereof in a cholestatic liver disease occurrence process, so that liver function indexes are recovered; the traditional Chinese medicine composition can be used for relieving liver pathological injury, including inhibiting bile duct hyperplasia, relieving portal vein inflammatory response and relieving portal vein fibrosis, so that the pathological development process of fibrosis and inflammation caused by the liver injury is blocked.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

Provided herein are methods for treating cholestasis in an individual having a liver disease. More specifically, the present invention relates to a method for treating progressive familial intrahepatic cholestasis (PFIC) in a subject wherein the method comprises administering to a subject in need thereof maxicabate.

The invention discloses a culture medium for colonization of intestinal flora and intestinal gas of gastrointestinal cancer crowds. The culture medium contains yeast extract, tryptone, mucoprotein, mycoprotein, insect protein, soybean protein, fructo-oligosaccharide, galactooligosaccharide, inulin, resistant dextrin, dietary fiber, porridge, vegetable juice, fruit juice, oat powder, coix seed powder, black bean powder, sialic acid, algal oil DHA, potassium chloride, sodium chloride, monopotassium phosphate, sodium sulfate, bile salt and a plant extract mixture. Vitamin mixed liquid and the like. By means of the bionic colon reactor, by referring to real in-vivo parameters of gastrointestinal cancer people, the real intestinal environment of domestic gastrointestinal cancer people is well simulated in vitro, the intestinal flora ecology and intestinal gas distribution are reproduced, and a normal intestinal microorganism and intestinal gas database of the gastrointestinal cancer people can be constructed. The method is beneficial to accurate diagnosis and personalized treatment of intestinal microecology of people with gastrointestinal cancer, and better evaluates the health state of people with gastrointestinal cancer and formulates preventive measures.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.